10x Genomics has recently made a significant move to elevate its capabilities in the realm of single cell experiments by acquiring Scale Biosciences. The acquisition deal involves a payment of $30 million in cash and stock upfront, with additional payments contingent on achieving specific milestones. This strategic move is set to integrate Scale’s technology and expertise into 10x Genomics, aligning visions for innovation and growth within the genomics industry.
Scale Biosciences, a smaller private company known for its innovative approach to single cell genomics, brings unique technology to the table. The company’s split-pool combinatorial barcoding methodology allows for enhanced scalability and complexity in single cell experiments. Key products include QuantumScale Single Cell RNA Kits, ScalePlex for pooling samples, and a Single Cell Methylation Kit, enabling the detection of methylation states at a single cell level.
10x Genomics’ CEO, Serge Saxonov, emphasizes the acquisition’s focus on driving innovation through increased scalability. While supporting Scale’s existing products and customer base, the primary goal is to integrate Scale’s technology into 10x’s Chromium portfolio to introduce new capabilities and expand the company’s offerings in the single cell genomics domain. The acquisition is seen as a step towards advancing technology and consolidating expertise to better serve the research community and impact human health positively.
Giovanna Prout, CEO of Scale Biosciences, expresses excitement about the acquisition, highlighting 10x Genomics as a market leader with a broad global reach. The move represents an opportunity for Scale’s technology to be part of a larger engine for innovation and growth within the genomics sector. The integration of Scale’s advanced technology into 10x Genomics is expected to facilitate the development of groundbreaking solutions that push the boundaries of single cell genomics research.
Renowned figures in the industry, such as Garry Nolan, co-founder of Scale Biosciences, and a professor at Stanford University, recognize the potential of this acquisition in furthering technological advancements. With a history of successful entrepreneurship and a track record of pioneering technologies, Nolan envisions the integration of Scale’s technology into 10x Genomics as a step towards merging different technological capabilities, such as spatial imaging and single cell analysis, to create comprehensive solutions for the scientific community.
The acquisition of Scale Biosciences by 10x Genomics marks a significant shift in the landscape of single cell genomics, with a focus on driving innovation, scalability, and technological integration. By combining resources, expertise, and visions for the future, both companies aim to leverage their strengths to deliver cutting-edge solutions that advance research in genomics and have a positive impact on human health.
Key Takeaways:
– The acquisition of Scale Biosciences by 10x Genomics aims to integrate innovative single cell genomics technology into the latter’s portfolio.
– The deal emphasizes driving innovation, scalability, and technological advancements in the genomics industry.
– Industry experts foresee the integration of Scale’s technology into 10x Genomics as a strategic move to consolidate expertise and offer comprehensive solutions in single cell genomics.
– The acquisition signifies a collaborative effort to push the boundaries of research and positively impact human health through advanced genomics solutions.
Tags: biotech
Read more on genengnews.com